YILING PHARMACEUTICAL(SZ:002603) Xin Lang Cai Jing·2025-11-11 02:56Group 1 - Yiling Pharmaceutical's stock increased by 5.63%, reaching 20.28 CNY per share, with a trading volume of 620 million CNY and a turnover rate of 2.32%, resulting in a total market capitalization of 33.882 billion CNY [1] - The company, established on August 28, 2001, and listed on July 28, 2011, is located in the High-tech Industrial Development Zone of Shijiazhuang, Hebei Province, focusing on the research, production, and sales of traditional Chinese medicine [1] - The revenue composition of Yiling Pharmaceutical includes cardiovascular products at 48.60%, respiratory system products at 22.80%, other products at 22.52%, and patented products at 6.08% [1] Group 2 - Among the top ten circulating shareholders of Yiling Pharmaceutical, a fund under Southern Fund holds a position, specifically the Southern CSI 500 ETF (510500), which reduced its holdings by 256,900 shares in the third quarter, now holding 12.1396 million shares, accounting for 0.88% of circulating shares [2] - The Southern CSI 500 ETF (510500), established on February 6, 2013, has a latest scale of 140.098 billion CNY, with a year-to-date return of 30.19%, ranking 1786 out of 4216 in its category, and a one-year return of 19.77%, ranking 2117 out of 3922 [2] - The fund manager, Luo Wenjie, has a cumulative tenure of 12 years and 207 days, managing assets totaling 170.445 billion CNY, with the best fund return during his tenure at 151.42% and the worst at -47.6% [2]